CS272759B2 - Method of lyophilized adsorbed multivalent vaccines preparation - Google Patents

Method of lyophilized adsorbed multivalent vaccines preparation Download PDF

Info

Publication number: CS272759B2
Authority: CS; Czechoslovakia
Prior art keywords: lyophilized; antigens; dose; concentrated; pertussis
Prior art date: 1983-02-22

Application number

CS122584A

Other languages

Czech (cs)

English (en)

Other versions

CS122584A2 (en

Inventor

Zoltan Dr Csizer

Karoly Dr Sikos

Laszlo Bacskai

Istvan Dr Joo

Eleonora Dr Niedermayer

Lajos Dr Rethy

Jozsef Dr Zsidai

Original Assignee

Human Oltoanyagtermelo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-02-22

Filing date

1984-02-22

Publication date

1991-02-12

1984-02-22 Application filed by Human Oltoanyagtermelo filed Critical Human Oltoanyagtermelo

1990-06-13 Publication of CS122584A2 publication Critical patent/CS122584A2/cs

1991-02-12 Publication of CS272759B2 publication Critical patent/CS272759B2/cs

Links

238000000034 method Methods 0.000 title claims abstract description 9
229940031348 multivalent vaccine Drugs 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims abstract description 6
102000036639 antigens Human genes 0.000 claims abstract description 27
108091007433 antigens Proteins 0.000 claims abstract description 27
239000000427 antigen Substances 0.000 claims abstract description 26
239000000463 material Substances 0.000 claims abstract description 18
201000005702 Pertussis Diseases 0.000 claims abstract description 13
230000001681 protective effect Effects 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims abstract description 9
230000008569 process Effects 0.000 claims abstract description 5
206010043376 Tetanus Diseases 0.000 claims abstract description 4
206010013023 diphtheria Diseases 0.000 claims abstract description 4
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 10
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
229960000814 tetanus toxoid Drugs 0.000 claims description 7
208000037386 Typhoid Diseases 0.000 claims description 3
239000006285 cell suspension Substances 0.000 claims description 3
229960003983 diphtheria toxoid Drugs 0.000 claims description 3
238000012792 lyophilization process Methods 0.000 claims description 3
201000008297 typhoid fever Diseases 0.000 claims description 3
241000588832 Bordetella pertussis Species 0.000 claims description 2
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 2
229960005486 vaccine Drugs 0.000 abstract description 22
239000000243 solution Substances 0.000 abstract description 10
229910019142 PO4 Inorganic materials 0.000 abstract description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 3
239000010452 phosphate Substances 0.000 abstract description 3
208000028104 epidemic louse-borne typhus Diseases 0.000 abstract description 2
239000002504 physiological saline solution Substances 0.000 abstract description 2
206010061393 typhus Diseases 0.000 abstract description 2
238000004108 freeze drying Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 9
238000001179 sorption measurement Methods 0.000 description 9
229920002307 Dextran Polymers 0.000 description 7
230000003053 immunization Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
229940024545 aluminum hydroxide Drugs 0.000 description 6
239000004576 sand Substances 0.000 description 6
230000007423 decrease Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 5
229960004906 thiomersal Drugs 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000004062 sedimentation Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
235000008733 Citrus aurantifolia Nutrition 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
240000006909 Tilia x europaea Species 0.000 description 3
235000011941 Tilia x europaea Nutrition 0.000 description 3
239000004571 lime Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
241000699670 Mus sp. Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
241000700198 Cavia Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108091007643 Phosphate carriers Proteins 0.000 description 1
206010057040 Temperature intolerance Diseases 0.000 description 1
CJIZDSMQDFSIAU-UHFFFAOYSA-J [OH-].[Al+3].P(=O)([O-])([O-])[O-].[Al+3] Chemical compound [OH-].[Al+3].P(=O)([O-])([O-])[O-].[Al+3] CJIZDSMQDFSIAU-UHFFFAOYSA-J 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
230000001147 anti-toxic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960001188 diphtheria antitoxin Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000008543 heat sensitivity Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229960005367 tetanus antitoxin Drugs 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

CS122584A 1983-02-22 1984-02-22 Method of lyophilized adsorbed multivalent vaccines preparation CS272759B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU83609A HU188847B (en)	1983-02-22	1983-02-22	Process for producing liophylized combined vaccines

Publications (2)

Publication Number	Publication Date
CS122584A2 CS122584A2 (en)	1990-06-13
CS272759B2 true CS272759B2 (en)	1991-02-12

Family

ID=10950430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS122584A CS272759B2 (en)	1983-02-22	1984-02-22	Method of lyophilized adsorbed multivalent vaccines preparation

Country Status (18)

Country	Link
US (1)	US4578270A (da)
JP (1)	JPS59196821A (da)
BE (1)	BE898955A (da)
CA (1)	CA1234048A (da)
CH (1)	CH663901A5 (da)
CS (1)	CS272759B2 (da)
DD (1)	DD216384A5 (da)
DE (1)	DE3406419A1 (da)
DK (1)	DK82784A (da)
ES (1)	ES529961A0 (da)
FR (1)	FR2541116B1 (da)
GB (1)	GB2135190B (da)
HU (1)	HU188847B (da)
IT (1)	IT1196032B (da)
NL (1)	NL8400511A (da)
PL (1)	PL246306A1 (da)
PT (1)	PT78132B (da)
YU (1)	YU33284A (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU188847B (en) *	1983-02-22	1986-05-28	Human Oltoanyagtermeloe Es Kutato Intezet,Hu	Process for producing liophylized combined vaccines
JPS62162963A (ja) *	1986-01-10	1987-07-18	Sadao Shiosaka	金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
GB8601279D0 (en) *	1986-01-20	1986-02-26	Public Health Lab Service	Purification of pertussis antigens
US4762710A (en) *	1986-06-16	1988-08-09	The United States Of America As Represented By The Department Of Health And Human Services	Novel method of preparing toxoid by oxidation and metal ions
CA1337859C (en) *	1987-04-24	1996-01-02	Masashi Chazono	Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5139776A (en) *	1987-04-24	1992-08-18	The Research Foundation For Microbial Diseases Of Osaka University	Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5290563A (en) *	1989-07-27	1994-03-01	Laboratoire Des Stallergenes	Method for combining a mixture of heterogeneous substances with liposomes
MX170503B (es) *	1990-05-10	1993-08-26	Univ Mexico	, "procedimiento para obtener un reactivo antigenico util para determinar indirectamente salmonella typhi.
GB9125695D0 (en) *	1991-12-03	1992-01-29	Mastavac Limited	Medical preparations
SG47725A1 (en) *	1992-10-27	1998-04-17	American Cyanamid Co	Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
EP0678035B9 (en) *	1993-01-08	2006-12-13	Csl Limited	Vaccine preparations
US6274552B1 (en)	1993-03-18	2001-08-14	Cytimmune Sciences, Inc.	Composition and method for delivery of biologically-active factors
US5902565A (en) *	1993-12-24	1999-05-11	Csl Limited	Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US20010055581A1 (en) *	1994-03-18	2001-12-27	Lawrence Tamarkin	Composition and method for delivery of biologically-active factors
US7229841B2 (en) *	2001-04-30	2007-06-12	Cytimmune Sciences, Inc.	Colloidal metal compositions and methods
US6407218B1 (en)	1997-11-10	2002-06-18	Cytimmune Sciences, Inc.	Method and compositions for enhancing immune response and for the production of in vitro mabs
RU2130778C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа НПК "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
RU2130779C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
GB2342922B (en) *	1998-10-19	2002-12-24	Jeyes Group Plc	Lavatory cleansing block
RU2277905C2 (ru) *	1999-08-24	2006-06-20	Тева Фармасьютикал Индастриз, Лтд.	Вакцинная композиция и способ ее применения
US6592869B2 (en) *	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
US8632785B2 (en) *	2000-02-08	2014-01-21	Allergan, Inc.	Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030138460A1 (en) *	2000-02-08	2003-07-24	Allergan, Inc	Methods of treating animals with botulinum toxin pharmaceutical compositions
EP1586329A1 (en) *	2000-02-08	2005-10-19	Allergan, Inc.	Botulinum toxin pharmaceutical compositions
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US7780967B2 (en)	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
NZ552576A (en) *	2000-06-08	2008-06-30	Powderject Vaccines Inc	Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
US20020120228A1 (en) *	2000-06-08	2002-08-29	Yuh-Fun Maa	Powder compositions
US20040213798A1 (en) *	2000-06-08	2004-10-28	Powderject Vaccines, Inc.	Spray-dried alum compositions
KR100401423B1 (ko) *	2001-01-10	2003-10-17	주식회사 엘지생명과학	혼합 백신의 제조 방법
WO2002101412A2 (en) *	2001-06-08	2002-12-19	Powderject Vaccines, Inc.	Spray freeze-dried compositions
WO2005065121A2 (en) *	2003-12-02	2005-07-21	Cytimmune Sciences, Inc.	Methods and compositions for the production of monoclonal antibodies
CA2554755A1 (en) *	2004-01-28	2005-08-11	Cytimmune Sciences, Inc.	Functionalized colloidal metal compositions and methods
AU2006299310A1 (en) *	2005-10-04	2007-04-12	Alk-Abello A/S	Solid vaccine formulation
US20110014118A1 (en) *	2007-09-21	2011-01-20	Lawrence Tamarkin	Nanotherapeutic colloidal metal compositions and methods
CA2700378A1 (en) *	2007-09-21	2009-03-29	Cytimmune Sciences, Inc.	Nanotherapeutic colloidal metal compositions and methods
EP2219458B1 (en) *	2007-11-08	2015-07-15	Cytimmune Sciences, Inc.	Compositions and methods for generating antibodies
GB0822633D0 (en) *	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB0916570D0 (en) *	2009-09-21	2009-10-28	Royal Holloway & Bedford New C	Method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2085391A (en) *	1934-01-31	1937-06-29	Sharp & Dohme Inc	Lyophilic biologically active substances and process of producing the same
US3097140A (en) *	1958-10-31	1963-07-09	Merck & Co Inc	Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
GB895073A (en) *	1959-11-23	1962-05-02	Wellcome Found	Immunising preparations containing clostridium perfringens toxins and toxoids
US3395219A (en) *	1964-12-11	1968-07-30	Merck & Co Inc	Process for production of pertussis antigen
NL6600706A (da) *	1965-02-05	1966-08-08
GB1081796A (en) *	1965-08-13	1967-08-31	Wright Fleming Inst Of Microbi	Improvements in or relating to oily adjuvants for water-in-oil emulsions of antigenic materials
US3405218A (en) *	1965-09-22	1968-10-08	Parke Davis & Co	Extracting bordetella pertussis antigens with lithium bromide
GB1145320A (en) *	1966-05-20	1969-03-12	Ustav Ser A Ockovacich Latek O	Process for the preparation of bacterial cultures for vaccines against pertussis and
GB1152607A (en) *	1967-03-08	1969-05-21	Pfizer Ltd	Antigenic Compositions
GB1218277A (en) *	1968-08-20	1971-01-06	Miles Lab	Dry water-dispersible aluminium hydroxide gels
US3599150A (en) *	1969-08-01	1971-08-10	Miles Lab	Stabilized aluminum hydroxide suspensions
FR2181426B1 (da) *	1972-04-06	1974-12-20	Pasteur Institut
FR2227861B1 (da) *	1973-05-04	1976-07-02	Anvar
DE2355094C3 (de) *	1973-11-03	1979-05-23	Behringwerke Ag, 3550 Marburg	Verfahren zur Herstellung eines Tetanus-Impfstoffs
DE2461439C3 (de) *	1974-12-24	1980-03-20	Behringwerke Ag, 3550 Marburg	Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel
JPS5296729A (en) *	1976-02-05	1977-08-13	Shionogi & Co Ltd	Mixed vaccin for cyanomycosis
US4273762A (en) *	1979-12-03	1981-06-16	Merck & Co., Inc.	Lyophilization process for live viral compositions
HU188847B (en) *	1983-02-22	1986-05-28	Human Oltoanyagtermeloe Es Kutato Intezet,Hu	Process for producing liophylized combined vaccines

1983
- 1983-02-22 HU HU83609A patent/HU188847B/hu not_active IP Right Cessation
1984
- 1984-02-15 GB GB08403921A patent/GB2135190B/en not_active Expired
- 1984-02-17 NL NL8400511A patent/NL8400511A/nl not_active Application Discontinuation
- 1984-02-20 FR FR8402511A patent/FR2541116B1/fr not_active Expired
- 1984-02-20 DD DD84260197A patent/DD216384A5/de not_active IP Right Cessation
- 1984-02-20 PT PT78132A patent/PT78132B/pt unknown
- 1984-02-20 BE BE1/10963A patent/BE898955A/fr not_active IP Right Cessation
- 1984-02-21 CH CH827/84A patent/CH663901A5/de not_active IP Right Cessation
- 1984-02-21 DK DK82784A patent/DK82784A/da not_active Application Discontinuation
- 1984-02-21 PL PL24630684A patent/PL246306A1/xx unknown
- 1984-02-21 IT IT19729/84A patent/IT1196032B/it active
- 1984-02-21 CA CA000447885A patent/CA1234048A/en not_active Expired
- 1984-02-22 ES ES529961A patent/ES529961A0/es active Granted
- 1984-02-22 JP JP59030463A patent/JPS59196821A/ja active Pending
- 1984-02-22 DE DE19843406419 patent/DE3406419A1/de not_active Withdrawn
- 1984-02-22 US US06/582,432 patent/US4578270A/en not_active Expired - Fee Related
- 1984-02-22 CS CS122584A patent/CS272759B2/cs unknown
- 1984-02-22 YU YU00332/84A patent/YU33284A/xx unknown

Also Published As

Publication number	Publication date
US4578270A (en)	1986-03-25
ES8506451A1 (es)	1985-07-16
DK82784D0 (da)	1984-02-21
FR2541116B1 (fr)	1988-07-15
DD216384A5 (de)	1984-12-12
GB2135190B (en)	1986-10-22
FR2541116A1 (fr)	1984-08-24
PL246306A1 (en)	1985-02-27
IT8419729A0 (it)	1984-02-21
YU33284A (en)	1987-10-31
BE898955A (fr)	1984-08-20
NL8400511A (nl)	1984-09-17
PT78132A (en)	1984-03-01
DK82784A (da)	1984-08-23
GB2135190A (en)	1984-08-30
DE3406419A1 (de)	1984-08-23
CA1234048A (en)	1988-03-15
JPS59196821A (ja)	1984-11-08
CH663901A5 (de)	1988-01-29
GB8403921D0 (en)	1984-03-21
IT1196032B (it)	1988-11-10
ES529961A0 (es)	1985-07-16
HU188847B (en)	1986-05-28
PT78132B (en)	1986-05-19
CS122584A2 (en)	1990-06-13

Publication	Publication Date	Title
CS272759B2 (en)	1991-02-12	Method of lyophilized adsorbed multivalent vaccines preparation
KR880001098B1 (ko)	1988-06-29	헤모필루스 인플루엔재 b 다당류 엑소톡소이드 배합체 왁진의 제조방법
EP0130619B1 (en)	1989-03-15	Hepatitis b vaccine and method for its preparation
CA1272952A (en)	1990-08-21	Glycoproteinic conjugates having trivalent immunogenic activity
KR100404312B1 (ko)	2004-02-11	폴리리보실리비톨포스페이트를함유한백신조성물과이들의제조방법
US3743720A (en)	1973-07-03	Dry water-dispersible aluminum hydroxide gels
Dupuy et al.	1975	Immunopathology of mouse hepatitis virus type 3 infection
WO2016155581A1 (zh)	2016-10-06	一种分离纯化的无细胞百白破-b型流感嗜血杆菌-A群C群脑膜炎球菌联合疫苗及其制备方法
KR100289224B1 (ko)	2001-05-02	조합 소아과 백신 조성물
DE19511276C2 (de)	1999-02-18	Adjuvans auf der Basis kolloidaler Eisenverbindungen
DE3787887T2 (de)	1994-02-10	Verfahren zum Züchten von Bordetella-Pertussis, ein Pertussis-Toxoid und ein Pertussis-Impfstoff.
PL211005B1 (pl)	2012-03-30	Sposób wytwarzania szczepionki zespolonej
CN116159134B (zh)	2024-11-26	七叶皂苷和/或其盐化合物作为佐剂在疫苗中的应用
EP3645045A1 (en)	2020-05-06	Novel multivalent polysaccharide protein conjugate vaccine composition and formulation thereof
Rolfe et al.	1965	Antigens of Bacteriophage øX174
Cooper et al.	1991	Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice
CN1282486C (zh)	2006-11-01	含至少两种效价的疫苗组合物,其一添有助剂,另一未添
US12268738B2 (en)	2025-04-08	Liquid six combined vaccine composition
EP0339531A1 (en)	1989-11-02	Physiological active liquid allergenic composition from biological raw materials
Hobson	1966	The strain-specific serological activity of a non-haemagglutinating fraction of influenza viruses
SE463958B (sv)	1991-02-18	Foerfarande foer framstaellning av lyofiliserade, adsorberade, polyvalenta vacciner
Srivastava et al.	1970	Immunization of mice with components of Pasteurella multocida
CA2525615C (en)	2012-03-13	Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
US6927235B2 (en)	2005-08-09	Vaccine composition comprising iron phosphate as vaccine adjuvant
Toyama et al.	1978	Inhibition of Sendai virus-induced hemolysis by concanavalin A